Technical Analysis for HALO - Halozyme Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 28.56 1.28% 0.36
HALO closed up 1.28 percent on Wednesday, August 12, 2020, on 1.16 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat
Historical HALO trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
MACD Bearish Signal Line Cross Bearish 1.28%
20 DMA Support Bullish 1.28%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.28%
Earnings Movers Other 1.28%
Down 3 Days in a Row Weakness 1.28%
Stochastic Sell Signal Bearish -0.28%
Earnings Movers Other -0.28%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human enzymes. Its research focuses on human enzymes that transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids, or to alter abnormal tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented human recombinant hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to increase the dispersion and absorption of other injected drugs; in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Ultrafast Insulin program, a Phase II clinical trial product for the treatment of type 1 and 2 diabetes mellitus; PEGPH20, a new molecular entity that is in Phase II clinical trial for the treatment of solid tumors; and HTI-501, a lysosomal proteinase, which is in Phase 1/2 clinical trial for the treatment of edematous fibrosclerotic panniculopathy. It has collaborative partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc.; Pfizer Inc.; Baxter Healthcare Corporation; ViroPharma Incorporated; and Intrexon Corporation for the development of three product candidates. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Biotechnology Biopharmaceutical Life Sciences Solid Tumors Antibodies Diabetes Mellitus Clinical Trial Product Hoffmann La Roche Halozyme Hyaluronidase

Is HALO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 29.6354
52 Week Low 12.71
Average Volume 1,213,130
200-Day Moving Average 21.27
50-Day Moving Average 26.55
20-Day Moving Average 28.12
10-Day Moving Average 28.43
Average True Range 1.02
ADX 14.75
+DI 19.63
-DI 21.96
Chandelier Exit (Long, 3 ATRs ) 26.56
Chandelier Exit (Short, 3 ATRs ) 29.32
Upper Bollinger Band 29.59
Lower Bollinger Band 26.66
Percent B (%b) 0.65
BandWidth 10.40
MACD Line 0.52
MACD Signal Line 0.56
MACD Histogram -0.0438
Fundamentals Value
Market Cap 3.82 Billion
Num Shares 134 Million
EPS -0.93
Price-to-Earnings (P/E) Ratio -30.71
Price-to-Sales 16.99
Price-to-Book 39.19
PEG Ratio -2.38
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.30
Resistance 3 (R3) 30.20 29.51 30.01
Resistance 2 (R2) 29.51 29.07 29.57 29.91
Resistance 1 (R1) 29.04 28.80 29.28 29.14 29.82
Pivot Point 28.35 28.35 28.47 28.41 28.35
Support 1 (S1) 27.88 27.91 28.12 27.98 27.30
Support 2 (S2) 27.19 27.64 27.25 27.21
Support 3 (S3) 26.72 27.19 27.11
Support 4 (S4) 26.82